Form 4: Zimmer Biomet CHRO Lori Winkler Reports RSU Vesting

Zimmer Biomet Holdings, Inc.'s SVP and CHRO, Lori Winkler, reported the vesting of restricted stock units and subsequent share transactions for tax obligations.

Summary

• Lori Winkler, SVP and CHRO, reported transactions related to her equity holdings in Zimmer Biomet Holdings, Inc. (ZBH).
• On February 25, 2026, 2,347 shares of common stock were acquired upon the vesting of restricted stock units (RSUs).
• Concurrently, 924 shares were disposed of at a price of $99.51 per share to satisfy tax withholding obligations associated with the RSU vesting.
• Following these transactions, Winkler directly beneficially owns 9,418 shares of common stock.
• One-third of her restricted stock units vested on February 25, 2026, with the remaining units scheduled to vest in two equal installments.
• Winkler now beneficially owns 4,693 derivative securities in the form of restricted stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects the normal course of executive compensation and continued executive ownership, but does not introduce new strategic information.

Positives

• The vesting of restricted stock units indicates the achievement of performance or time-based criteria, aligning executive incentives with shareholder interests.
• The executive continues to hold a significant number of shares (9,418 common shares and 4,693 RSUs), demonstrating ongoing alignment with the company's performance.

Negatives

• The disposition of 924 shares, while for tax purposes, represents a reduction in the executive's direct common stock holdings.

Future Outlook

Remaining restricted stock units are scheduled to vest in two equal installments on February 25, 2027, and February 25, 2028, indicating future equity compensation events.

Industry Context

StockSavvy.ai notes that routine Form 4 filings like this are common for executives receiving equity compensation. The vesting of RSUs and subsequent sale for tax purposes is a standard practice in executive compensation plans across the medical device industry, reflecting the realization of previously granted awards.

Comparison to Industry Standards

• This transaction is a standard practice for executive equity compensation.
• Companies like Medtronic (MDT), Stryker (SYK), and Johnson & Johnson (JNJ) also utilize restricted stock units as a key component of their executive incentive programs, with similar vesting schedules and tax withholding procedures upon vesting.
• The reported share price of $99.51 for tax disposition is specific to ZBH's market value at the time and not directly comparable as a performance metric to other companies' share prices.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate a significant change in company strategy or financial health. It confirms executive alignment through equity ownership.
• Employees: No direct impact on general employees.

Next Steps

• One-half of the remaining restricted stock units are scheduled to vest on February 25, 2027.
• The final one-half of the remaining restricted stock units are scheduled to vest on February 25, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU vesting and tax-related share disposition) and does not contain new material information that would alter the fundamental investment thesis for Zimmer Biomet Holdings, Inc. Investors should continue to hold based on broader company performance and industry outlook rather than this standard insider transaction.

Keywords

Zimmer Biomet, ZBH, Lori Winkler, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Share Ownership, Tax Withholding